Trial Profile

A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 02 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EIK 1001 (Primary) ; Carboplatin; Paclitaxel; Pembrolizumab; Pemetrexed
Indications Non-small cell lung cancer
Focus Adverse reactions
Acronyms TeLuRide-005
Sponsors Eikon Therapeutics

29 May 2025 According to an Eikon Therapeutics media release, data from this study will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 30 - June 3, 2025, in Chicago, Illinois.
04 Jun 2024 Trial designs presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
28 May 2024 According to an Eikon Therapeutics media release, data from this study will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago May 31-June 4, 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com